NASDAQ: PRQRProqr Therapeutics Nv Stock
$1.52-0.04 (-2.56%)
Updated Jun 16, 2026
PRQR Price
$1.52
Fair Value Price
N/A
Market Cap
$163.72M
52 Week Low
$1.33
52 Week High
$3.10
P/E
-3x
P/B
3.7x
P/S
10.89x
PEG
N/A
Dividend Yield
N/A
Revenue
$16.05M
Earnings
-$52.29M
Gross Margin
100%
Operating Margin
-322.16%
Profit Margin
-333.5%
Debt to Equity
1.63
Operating Cash Flow
-$57M
Beta
1.06
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
PRQR Overview
ProQR Therapeutics N.V. operates as a biopharmaceutical enterprise dedicated to discovering and developing RNA-based therapies designed to address genetic disorders. The company's pipeline includes two primary drug candidates in advanced clinical stages: Sepofarsen is currently in a Phase II/III clinical trial, known as the ILLUMINATE trial, targeting Leber Congenital Amaurosis 10 (LCA10). Ultevursen is also undergoing Phase II/III evaluation for the treatment of USH2A-mediated retinitis pigmentosa and Usher syndrome. Beyond its clinical programs, ProQR is actively developing its proprietary Axiomer RNA base-editing platform technology. Strategic collaborations are central to ProQR's strategy, evidenced by its licensing agreements with institutions such as Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center. Furthermore, a significant license and research partnership exists with Eli Lilly and Company, focused on the discovery, advancement, and commercialization of novel medicines for genetic conditions impacting the liver and nervous system. Established in 2012, ProQR Therapeutics N.V. maintains its corporate headquarters in Leiden, the Netherlands.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine PRQR's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
PRQR
Ranked#454 of 462
Ranked#454 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $226.88 | A | |
| $52.10 | A | |
| $16.22 | A |
Be the first to know about important PRQR news, forecast changes, insider trades & much more!
PRQR News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how PRQR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PRQR is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PRQR is good value based on its book value relative to its share price (3.7x), compared to the US Biotechnology industry average (4.86x)
P/B vs Industry Valuation
PRQR is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more PRQR due diligence checks available for Premium users.
Valuation
PRQR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3x
Industry
16.03x
Market
13.25x
PRQR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.7x
Industry
4.86x
PRQR is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PRQR's financial health
Profit margin
Revenue
$2.3M
Net Income
-$15.4M
Profit Margin
-658.3%
PRQR's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
PRQR's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$113.8M
Liabilities
$70.6M
Debt to equity
1.63
PRQR's short-term assets ($102.33M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PRQR's short-term assets ($102.33M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PRQR's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
PRQR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$13.2M
Investing
-$188.5k
Financing
-$349.4k
PRQR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PRQR vs Biotech Stocks
Proqr Therapeutics Nv Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.